



Livingstone Health Holdings Limited

FY2022 Annual General Meeting
29 July 2022



AGENDA

- **Corporate Developments
for FY2022**
- **Financial Highlights**
- **Outlook**

Corporate Developments for FY2022

September 2021

- Build on the multi-disciplinary ecosystem - Launch of Atlas Podiatry and Physiotherapy, our allied healthcare service



March 2022

- Strengthening internal pillars - Appointment of Dr Chua Hshan Cher as Deputy CEO
- Signed partnership with Phytopharma & Truth Asset Management to pursue healthcare opportunities in Vietnam



May 2022

- Exceeding Targets - Deferred consideration for RTO paid to Vendors, as the Group exceeded RTO profit target
- Share capital base enlarged by 117.5 million new shares (total issued shares: 436.4 million)



June 2022

- Expand healthcare value chain - Signed MoU with ASX-listed Osteopore to develop 3D-printed bio-resorbable implants for bone and tissue healing



FY2022 Financial Snapshot

FY2022 Financial Snapshot

S\$'000	FY2022 12 Months Ended 31 March 2022	FY2021 15 Months Ended 31 March 2021	Change (%)
<u>Continuing Operations</u>			
Revenue	34,141	24,278	41
Profit Before Tax	4,249	4,116	3
Net Loss/Profit After Tax Attributable to Owner of the Company	3,025	(16,693)*	n.m [^]
*after accounting for exceptional items of:			
- RTO-related costs	-	(1,423)	n.m
- Loss on Reverse Acquisition	-	(18,892)	

[^]n.m: Not Meaningful

Balance Sheet

S\$('000)	31 March 2022	31 March 2021	Change (%)
Total Assets	21,086	20,281	4
Total Liabilities	15,396	18,376	16
Total Equity	5,690	1,905	199
Cash and Cash Equivalents	5,353	6,775	(21)
Net Assets Value Per Share (cents) Excluding Exceptional Items	1.57	0.48	227

FY2022 Results Highlights

- Revenue for 12-month FY2022 rose 41% to S\$34.1 million from S\$24.3 million for 15-month FY2021
- All segments improved performance despite challenges of the pandemic
- The Group continues to benefit from post-RTO growth strategies; added specialists to its pool of 16 doctors practising at 13 medical clinics
- Local and foreign patient foot traffic expected to increase with the easing of travel restrictions
- Proposed final dividend of 0.12 Singapore cent per share – its maiden dividend since completing its RTO in February 2021



Outlook

Outlook

01

Local and foreign patient foot traffic expected to rise as travel and movement restrictions in Singapore ease

02

Singapore's "Healthier SG" strategy will benefit PMG; network expansion will increase revenue

03

Livingstone Health will continue organic growth strategy and remain nimble for regional opportunities

04

Macro uncertainties and disruptions to supply chains will result in higher cost of medical supplies and operations



THANK YOU

MEDIA & INVESTOR CONTACT:

WER1 CONSULTANTS PTE LTD

TEL: (+65) 6721 7161

Isaac Tang: livingstone@wer1.net